Publications

Access hundreds of peer-reviewed cognitive research papers published by leading neuroscientists using Cogstate technology.

Search

Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls.

Authors: Anderson J, Bagkeris E, Boffito M, De Francesco D, Johnson M, Mallon P, Post FA, Sabin CA, Underwood J, Vera JH, Williams I, Winston A

Journal: HIV Medicine

DOI: 10.1111/hiv.12714

Year Published: 2019

OBJECTIVES: We investigated whether differences in cognitive performance between people living with HIV (PLWH) and comparable HIV-negative people were mediated or moderated by depressive symptoms and lifestyle factors. METHODS: A cross-sectional study of 637 ‘older’ PLWH aged ≥ 50 years, 340 ‘younger’ PLWH aged < 50 years and 276 demographically matched HIV-negative controls aged ≥ […]

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.

Authors: Edelstein H, Maruff P, Robertson K, Ross LL, Shaefer MS, Small CB, Wohl D

Journal: Journal of Neurovirology

DOI: 10.1007/s13365-018-0680-y

Year Published: 2019

Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, learning, and working memory in 293 HIV-1-infected, ART-experienced, and virologically suppressed adults. The ASSURE study randomized participants 1:2 to […]

Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition.

Authors: Boffito M, Elliot ER, Fitzpatrick C, McClure M, Miller RF, Moyle G, Simmons B, Singh S, Vera JH, Wang X

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

DOI: 10.1093/cid/ciy426

Year Published: 2019

Background: Demographic data show an increasingly aging human immunodeficiency virus (HIV) population worldwide. Recent concerns over dolutegravir-related neuropsychiatric toxicity have emerged, particularly amongst older people living with HIV (PLWH). We describe the pharmacokinetics (PK) of dolutegravir (DTG) 50 mg once daily in PLWH aged 60 and older. Additionally, to address calls for prospective neuropsychiatric toxicodynamic […]

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Authors: Alonso J, Barber TJ, Boffito M, Davies N, Fortuny R, Gazzard B, Imaz A, Mandalia S, Niubó J, Podzamczer D, Pozniak A

Journal: Journal of Neurovirology

DOI: 10.1007/s13365-017-0600-6

Year Published: 2018

CINAMMON is a phase IV, open-label, single-arm, pilot study assessing maraviroc (MVC) in the central nervous system (CNS) when added to darunavir/ritonavir monotherapy (DRV/r) in virologically suppressed HIV-infected subjects. CCR5 tropic participants on DRV/r were recruited. Participants remained on DRV/r for 12 week (w) (control phase). MVC 150 mg qd was added w12-w36 (intervention phase). […]

Effects of Recent Alcohol Consumption Level on Neurocognitive Performance in HIV+ Individuals.

Authors: Douglas-Newman KR, Kranzler HR, Pond T, Smith RV, Spiers MV

Journal: Addictive Disorders & their Treatment

DOI: 10.1097/ADT.0000000000000109

Year Published: 2017

OBJECTIVES: Although HIV+ individuals may be at increased risk of alcohol-related cognitive impairment, the relations between drinking level and cognitive performance in these individuals are not well understood. We examined whether higher levels of recent drinking in HIV+ individuals were associated with poorer cognitive performance, particularly in executive functioning (EF) and memory. METHODS: We administered […]

HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment.

Authors: Brew B, Carroll A

Journal: F1000Research

Year Published: 2017

HIV-associated neurocognitive disorders (HAND) remain prevalent despite plasma viral suppression by antiretroviral agents. In fact, the prevalence of milder subtypes of cognitive impairment is increasing. Neuropsychologic testing remains the “gold standard” of diagnosis; however, this is time consuming and costly in a resource-poor environment. Recently developed screening tools, such as CogState and the revised HIV […]

Does efavirenz replacement improve neurological function in treated HIV infection?

Authors: Anderson KN, Blamire A, Chadwick TJ, Hynes AM, Parikh J, Payne B, Price DA, Qian J, Wilkinson J

Journal: HIV Medicine

DOI: 10.1111/hiv.12503

Year Published: 2017

OBJECTIVES: The contribution of specific antiretroviral drugs to cognitive function in HIV-infected people remains poorly understood. Efavirenz (EFV) may plausibly cause cognitive impairment. The objective of this study was therefore to determine whether chronic EFV therapy is a modifier of neurocognitive and neurometabolic function in the setting of suppressive highly active antiretroviral therapy. METHODS: We […]

Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.

Authors: Bloch M, Brew BJ, Carberry A, Cysique LA, Kamminga J, Vincent T

Journal: Journal of Clinical and Experimental Neuropsychology

DOI: 10.1080/13803395.2016.1263282

Year Published: 2017

INTRODUCTION: The current study sought to determine the optimal impairment rating definition for a new HIV-associated neurocognitive disorder (HAND) screening procedure as compared to standard neuropsychological testing. METHOD: A total of 55 HIV-infected (HIV+; 19% AIDS; 87% on combination antiretroviral therapy, cART; 80% plasma undetectable) and 22 demographically comparable HIV-uninfected (HIV-) control adults (all male) […]

Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV.

Authors: Anderson J, Boffito M, De Francesco D, Mallon PW, Post FA, Sabin C, Sachikonye M, Underwood J, Vera JH, Williams I, Winston A

Journal: HIV Medicine

DOI: 10.1111/hiv.12434

Year Published: 2016

OBJECTIVES: While cognitive impairment is frequently reported in HIV-positive individuals and has historically been associated with poorer functional outcomes, the associations between cognitive impairment and patient-reported outcome measures (PROMs) in contemporary cohorts are unclear. METHODS: We tested cognitive function using a computerized battery (CogState™ ) in 290 HIV-positive and 97 HIV-negative individuals aged ≥ 50 […]

A Randomized Controlled Trial to Evaluate if Computerized Cognitive Rehabilitation Improves Neurocognition in Ugandan Children with HIV.

Authors: Boivin MJ, Giordani B, Nakasujja N, Opoka RO, Sikorskii A

Journal: AIDS Research and Human Retroviruses

DOI: 10.1089/AID.2016.0026

Year Published: 2016

OBJECTIVES: Clinically stable children with HIV can have neuromotor, attention, memory, visual-spatial, and executive function impairments. We evaluated neuropsychological and behavioral benefits of computerized cognitive rehabilitation training (CCRT) in Ugandan HIV children. DESIGN: One hundred fifty-nine rural Ugandan children with WHO Stage I or II HIV disease (6 to 12 years; 77 boys, 82 girls; […]

A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review.

Authors: Bailey M, Bloch M, Brew B, Carberry A, Cysique LA, Jayewardene A, Kamminga J, Maruff P, Quan D, Vincent T

Journal: Clinical Infectious Diseases

DOI: 10.1093/cid/ciw399

Year Published: 2016

BACKGROUND: Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) are not routinely assessed due to the lack of an adequate screening strategy. We aimed to develop a clinically relevant screening procedure for symptomatic HAND, validated against a gold standard neuropsychological (NP) test battery. METHODS: Representative HIV-infected (HIV+) and demographically matched HIV-uninfected (HIV-) participants in an observational […]

A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors.

Authors: Asboe D, Barber TJ, Boffito M, Hill A, Jagjit Singh G, Moyle G, Nelson M, Scourfield A, Waters L, Yapa HM

Journal: HIV Clinical Trials

DOI: 10.1080/15284336.2016.1176305

Year Published: 2016

BACKGROUND: Ongoing inflammation in controlled HIV infection contributes to non-AIDS comorbidities. High bilirubin appears to exhibit an anti-inflammatory effect in vivo. We therefore examined whether increased bilirubin in persons with HIV was associated with differences in markers of inflammation and cardiovascular, bone, renal disease, and neurocognitive (NC) impairment. METHODS: This cross-sectional study examined inflammatory markers […]

Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls.

Authors: Allsop J, Ashby J, Fidler S, Foster C, Garvey L, Paramesparan Y, Taylor-Robinson SD, Wan T, Winston A

Journal: HIV Clinical Trials

DOI: 10.1179/1528433614Z.0000000003

Year Published: 2015

BACKGROUND: Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC function in this group is sparse and control data lacking. We compared cerebral function in young adults with PaHIV infection to aged matched HIV negative family controls. […]

A pilot study of the neuropsychological benefits of computerized cognitive rehabilitation in Ugandan children with HIV.

Authors: Bangirana P, Boivin MJ, Busman RA, Giordani B, Opoka RO, Page CF, Parikh SM

Journal: Neuropsychology

DOI: 10.1037/a0019312

Year Published: 2010

OBJECTIVE: Because antiretroviral treatment (ART) fails to improve neurocognitive impairment in children with HIV, we completed a pilot study evaluating the feasibility and cognitive benefit of computerized cognitive rehabilitation therapy (CCRT) in Ugandan children with HIV. METHOD: Sixty Ugandan children with HIV (23 on ART) were randomly assigned to 10 sessions of Captain’s Log CCRT […]

Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors.

Authors: Barber TJ, Boffito M, Hill A, Moyle G, Nelson M, Singh GJ

Journal: Journal of the International AIDS Society

DOI: 10.7448/IAS.17.4.19827

Year Published: 2014

INTRODUCTION: Use of some protease inhibitors (PI) is associated with unconjugated hyperbilirubinaemia (HBR), due to inhibition of UGT1A1. As observed in Gilbert’s syndrome, HBR may have antioxidant and anti-inflammatory effects. Inflammation may be relevant to neurocognitive (NC) impairment, cardiovascular, renal and bone co-morbidities in HIV infection. This study aimed to analyse correlations between antiretroviral associated […]

1 2

Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults.

Authors: Baker JE, Bruns L Jr, Hassenstab J, Lim YY, Maruff P, Masters CL

Journal: Journal of Clinical and Experimental Neuropsychology

DOI: 10.1080/13803395.2019.1665626

Year Published: 2020

Introduction: Despite the numerous episodic memory tasks used in neuropsychological assessment, relatively few learning tasks are available, with methods lacking the complexity and sophistication to capture very subtle changes in information acquisition. Method: We adapted a previously validated associative learning task for use within an online framework, utilizing real-world stimuli, in which learning of audio-visual […]

Hippocampal segmentation for brains with extensive atrophy using three-dimensional convolutional neural networks.

Authors: Adamo S, Akhavein H, Black SE, Gao F, Goubran M, Holmes M, MacIntosh B, Martel A, Masellis M, Nestor S, Ntiri EE, Ozzoude M, Ramirez J, Scott C, Swardfager W, Swartz R

Journal: Human brain mapping

DOI: 10.1002/hbm.24811

Year Published: 2020

Hippocampal volumetry is a critical biomarker of aging and dementia, and it is widely used as a predictor of cognitive performance; however, automated hippocampal segmentation methods are limited because the algorithms are (a) not publicly available, (b) subject to error with significant brain atrophy, cerebrovascular disease and lesions, and/or (c) computationally expensive or require parameter […]

Identification of Pre-Clinical Alzheimer’s Disease in a Population of Elderly Cognitively Normal Participants.

Authors: Doecke JD, Maruff P, Mengersen K, Rousseau J, van Havre Z, Villemagne VL, White N

Journal: Journal of Alzheimer's disease : JAD

DOI: 10.3233/JAD-191095

Year Published: 2020

Alzheimer’s disease (AD) has a long pathological process, with an approximate lead-time of 20 years. During the early stages of the disease process, little evidence of the building pathology is identifiable without cerebrospinal fluid and/or imaging analyses. Clinical manifestations of AD do not present until irreversible pathological changes have occurred. Given an opportunity to provide […]

The Effect of Hearing Aid Use on Cognition in Older Adults: Can We Delay Decline or Even Improve Cognitive Function?

Authors: Busby P, Harris D, Launer S, Lemke U, Maruff P, Sarant J, Schembri A

Journal: Journal of clinical medicine

DOI: 10.3390/jcm9010254

Year Published: 2020

Hearing loss is a modifiable risk factor for dementia in older adults. Whether hearing aid use can delay the onset of cognitive decline is unknown. Participants in this study (aged 62-82 years) were assessed before and 18 months after hearing aid fitting on hearing, cognitive function, speech perception, quality of life, physical activity, loneliness, isolation, […]

Associations of Apolipoprotein E ε4 Genotype and Ball Heading With Verbal Memory in Amateur Soccer Players.

Authors: Davies P, Freudenberg-Hua Y, Hu S, Hunter LE, Kim M, Lipton ML, Lipton RB, Srinivasan P, Stewart WF

Journal: JAMA Neurology

DOI: 10.1001/jamaneurol.2019.4828

Year Published: 2020

Importance: Emerging evidence suggests that long-term exposure to ball heading in soccer, the most popular sport in the world, confers risk for adverse cognitive outcomes. However, the extent to which the apolipoprotein E ε4 (APOE ε4) allele, a common risk factor for neurodegeneration, and ball heading are associated with cognition in soccer players remains unknown. […]

Tags

There are no tags for this publication.

Rates of age- and amyloid β-associated cortical atrophy in older adults with superior memory performance.

Authors: Ames D, Dang C, Doecke JD, Fripp J, Harrington KD, Hickey M, Laws SM, Lim YY, Maruff P, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Snyder PJ, Sohrabi HR, Villemagne VL, Weinborn M, Xia Y, Yassi N

Journal: Alzheimer's & dementia : diagnosis assessment & disease monitoring

DOI: 10.1016/j.dadm.2019.05.005

Year Published: 2019

Introduction: Superior cognitive performance in older adults may reflect underlying resistance to age-associated neurodegeneration. While elevated amyloid β (Aβ) deposition (Aβ+) has been associated with increased cortical atrophy, it remains unknown whether “SuperAgers” may be protected from Aβ-associated neurodegeneration. Methods: Neuropsychologically defined SuperAgers (n = 172) and cognitively normal for age (n = 172) older […]

SuperAging: Current findings yield future challenges-A response to Rogalski and Goldberg.

Authors: Dang C, Maruff P

Journal: Alzheimer's & dementia : diagnosis assessment & disease monitoring

DOI: 10.1016/j.dadm.2019.05.004

Year Published: 2019

Tags

There are no tags for this publication.

Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer’s Disease.

Authors: Ames D, Chen C, Desmond PM, Fowler C, Hilal S, Kuijf H, Lim YY, Martins R, Maruff P, Masters CL, Rowe C, Salvado O, Villemagne V, Watson R, Xia Y, Yassi N, Yates P

Journal: Journal of Alzheimer's disease : JAD

DOI: 10.3233/JAD-191028

Year Published: 2019

BACKGROUND: Quantifying the contribution of cerebrovascular disease to the clinical and pathological profile of Alzheimer’s disease is challenging. OBJECTIVE: We aimed to determine the influence of cerebrovascular disease, amyloid-β (Aβ), and their comorbidity on cognitive decline, hippocampal atrophy, and Aβ deposition, by evaluating data from the Australian Imaging, Biomarker and Lifestyle Study of Ageing. METHODS: […]

Identification of Pre-Clinical Alzheimer’s Disease in a Population of Elderly Cognitively Normal Participants.

Authors: Doecke JD, Maruff P, Mengersen K, Rousseau J, van Havre Z, Villemagne V, White N

Journal: Journal of Alzheimer's disease : JAD

DOI: 10.3233/JAD-191095

Year Published: 2019

Alzheimer’s disease (AD) has a long pathological process, with an approximate lead-time of 20 years. During the early stages of the disease process, little evidence of the building pathology is identifiable without cerebrospinal fluid and/or imaging analyses. Clinical manifestations of AD do not present until irreversible pathological changes have occurred. Given an opportunity to provide […]

C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial.

Authors: Loebel A, Pikalov A, Raison CL, Siu C, Tocco M

Journal: Brain behavior and immunity

DOI: 10.1016/j.bbi.2019.12.010

Year Published: 2019

This study sought to investigate associations between levels of high-sensitivity c-reactive protein (hsCRP) prior to treatment and change in depressive symptoms and cognition in a short-term, double-blind, placebo-controlled study of lurasidone in children and adolescents with bipolar I depression. Patients 10-17 years of age with a DSM-5 diagnosis of bipolar I depression were randomized to […]

Tags

There are no tags for this publication.

Neuropsychological Trajectories Associated with Adolescent Alcohol and Cannabis Use: A Prospective 14-Year Study.

Authors: Coronado C, Courtney KE, Infante MA, Jacobus J, Nguyen-Louie TT, Worley M

Journal: Journal of the International Neuropsychological Society : JINS

DOI: 10.1017/S1355617719001395

Year Published: 2019

OBJECTIVES: Alcohol and cannabis remain the substances most widely used by adolescents. Better understanding of the dynamic relationship between trajectories of substance use in relation to neuropsychological functioning is needed. The aim of this study was to examine the different impacts of within- and between-person changes in alcohol and cannabis use on neuropsychological functioning over […]

Effects of transcranial direct current stimulation on cognition and symptoms in Chinese patients with schizophrenia✰.

Authors: Davis JM, Faull R, Jiang J, Jin H, Li C, Md WL, Smith RC, Szabo V, Wang J, Wang Y

Journal: Psychiatry Research

DOI: 10.1016/j.psychres.2019.112617

Year Published: 2019

There is preliminary evidence that transcranial direct current stimulation(tDCS) may improve symptoms and cognitive function in schizophrenia, but the generalizability of these results needs further investigation. We present a study of the effects of active vs. sham tDCS on cognition and symptoms in a sample of 45 Chinese patients with schizophrenia who showed significant cognitive […]

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.

Authors: Amariglio RE, Buckley R, Johnson KA, Maruff P, Masters CL, Mormino E, Papp KV, Rentz DM, Sperling RA, Villemagne VL

Journal: Alzheimer's & Dementia

DOI: 10.1016/j.jalz.2019.09.074

Year Published: 2019

INTRODUCTION: Demonstrating the “clinical meaningfulness” of slowing early cognitive decline in clinically normal (CN) older adults with elevated amyloid-β (Aβ+) is critical for Alzheimer’s disease secondary prevention trials and for understanding early cognitive progression. METHODS: Cox regression analyses were used to determine whether 3-year slopes on the preclinical Alzheimer’s cognitive composite predicted MCI diagnosis and […]

Computerized cognitive performance assessments in the Brooklyn Cognitive Impairments in Health Disparities Pilot Study.

Authors: Adler K, Apple S, Cheng F, Cohen C, Friedlander A, Gustafson D, Levine SR, Lucchesi M, Maruff P, Reinhardt M, Salmieri M, Stevens D, Weingast S

Journal: Alzheimer's & Dementia

DOI: 10.1016/j.jalz.2019.07.004

Year Published: 2019

INTRODUCTION: Detecting cognitive impairment in diverse, health disparities communities is an urgent health care priority. METHODS: The Brooklyn Cognitive Impairments in Health Disparities Pilot Study investigated quantitative aspects and liking of a computerized cognitive performance assessment, Cognigram, among individuals ≥ 40 years in traditional and nontraditional primary care settings. RESULTS: Cognigram was piloted in the […]

Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.

Authors: Awada G, De Cremer J, De Ridder M, Leys C, Neyns B, Rogiers A, Schembri A, Theuns P

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

DOI: 10.1007/s00520-019-05168-3

Year Published: 2019

PURPOSE: The aim of this study was to assess the evolution of health-related quality of Life (HRQoL), emotional burden, and neurocognitive function in the first-generation metastatic melanoma survivors treated with pembrolizumab. METHODS: Survivors were defined as patients who achieved a durable remission for at least 6 months after initiating pembrolizumab in a single-center observational study […]